File: '\\swfile\EmailIn\20251110 101615 Attachment Asep NR_Bondent agreement_Murphy _1110025_FINAL.docx'

Asep Medical Holdings Inc.

Asep Medical Holdings Licenses its Anti-Biofilm Technology to

Bondent Group for Oral Rinse Development and

Commercialization in China

November 10, 2025 - Asep Medical Holdings Inc. ("Asep Medical" or the "Company") (CSE: ASEP; OTCQB: SEPSF; FSE: JJ8) is pleased to announce that on August 1, 2025, the Company entered into a Patent Licensing Agreement (the "Agreement") with Shanghai Bondent Technology Co., Ltd. ("Bondent"), a leading China-based dental-medical company, to develop and commercialize a new oral rinse incorporating Asep Medical's patented anti-biofilm peptide technology, as the active ingredient.

Under the Agreement, Bondent will oversee the development, clinical trials, and marketing of an oral rinse in key global dental markets, beginning with China, through its extensive network of dental clinics, distributors, and training platforms. In return, Asep Medical's subsidiary, ABT Innovations Inc., will earn a 10% royalty on all sales of the oral rinse. Bondent will retain the rights to use the technology in the following territories: the People's Republic of China, Taiwan, Mongolia, North Korea, South Korea, Thailand, Papua New Guinea, Vietnam, Indonesia, the Philippines, Malaysia, the Russian Federation, Singapore, Hong Kong, and Macao.

Asep Medical's proprietary peptides are designed to selectively attack and disrupt bacterial biofilms, the protective communities of microbes that adhere to surfaces and are responsible for an estimated 65% of all infections. Biofilms are notoriously difficult to treat, highly resistant to antibiotics and, to date, have no FDA-approved targeted therapies. Biofilms are the primary cause of dental diseases.

The Company holds, through its subsidiary ABT Innovations Inc., an exclusive global license to this patented peptide technology, developed by world-renowned microbiologist Dr. Robert E.W. Hancock and his team at the University of British Columbia. These peptides have demonstrated potent anti-biofilm and anti-inflammatory activity and are in advanced development for multiple applications, including oral rinses and wound dressings.

"This agreement with Bondent is a major milestone in our strategy to bring truly novel anti-biofilm solutions to large global markets," said Dr. Robert Hancock, CEO of Asep Medical. "Bondent's strength in dental equipment, services and education, combined with our patented peptide technology, creates a powerful partnership to address chronic oral biofilm infections that current products simply do not resolve. We believe this oral rinse has the potential to set a new standard of care for dentists and their patients worldwide."

The oral rinse is being designed as a next-generation product for the prevention and mitigation of erosive dental biofilm infections that can lead to periodontitis, peri-implantitis, and other chronic oral conditions. Previous feasibility work with Asep Medical's peptide mouthwash has shown promising activity against oral biofilms in preclinical and early clinical settings.

OTHER NEWS

The Company also announces that Mr. Timothy Murphy has informed the Company's Board of Directors of his decision to step down as Chief Operating Officer, Corporate Secretary and a member of the Board of Directors, effective October 31, 2025.

Mr. Murphy's departure from these roles is part of a strategic transition within the Asep Medical Holdings Inc. group of companies. He will assume a board position with Sepset Biosciences Inc. (Sepset), a subsidiary of Asep Medical, where he will take on an expanded leadership role to advance the commercialization of SepsetER, Sepset's proprietary and highly anticipated sepsis diagnostic technology, currently in advanced development.

"We sincerely thank Timothy for his leadership and operational contributions to Asep Medical," said Dr. Robert Hancock, CEO. "His deep understanding of licensing, our technology and markets makes him ideally positioned to assist in accelerating the commercialization of SepsetER."

Mr. Murphy expressed his enthusiasm for the transition, stating, "SepsetER has the potential to transform how sepsis is diagnosed and treated. I'm excited to dedicate my focus to bringing the SepsetER technology to market."

The Company confirms that the transition was mutually agreed upon and reflects Asep Medical's commitment to aligning leadership resources with its key strategic priorities in infectious disease diagnostics and therapeutics.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical is a standout biotechnology research and development company based in Victoria, BC, Canada. The Company possesses a valuable portfolio of global patents for innovative diagnostic and therapeutic medical technologies. These technologies were developed over the past decade at the University of British Columbia under the guidance of Dr. Robert E. W. Hancock, one of the world's foremost microbiologists and the CEO of Asep. Asep holds a controlling interest in two private subsidiary companies - Sepset Biosciences (Asep's leading product, a sepsis diagnostic technology) and ABT Innovations (specializing in anti-biofilm technology). As the Company's patented innovations address unmet medical needs, it presents a unique investment opportunity for both retail and institutional investors. It is also an attractive buyout target for a major global pharmaceutical operator.

ABOUT BONDENT

Bondent is a China-based dental and medical platform that provides integrated services for dental institutions worldwide. Founded in 2009, the company is headquartered in Shanghai (Jiading District). It employs over 1,000 staff members, operates multiple subsidiaries and offices, and serves a wide network of dental practitioners.

FOR MORE INFORMATION, PLEASE CONTACT

Chris Dallin

Asep Medical Holdings Inc.

E. chris@asepmedical.com

T. 604-362-3654

FORWARD-LOOKING STATEMENTS

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plans," "continues," "expects," "projects," "intends," "believes," "estimates," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements include but are not limited to the successful execution of the Company's business plan, the development, testing, and commercialization of its sepsis diagnostic test (Sepset), and other statements regarding the Company's proposed business plans and technologies. Various assumptions were used in drawing conclusions or making the predictions contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks, including the risk that the Company's products may not perform as expected, may not receive regulatory approvals, or may not generate revenue as anticipated. Additional risk actors are identified in the Asep Medical Holdings Inc. prospectus dated November 9, 2021, and in the Company's management discussion and analysis, available for review under the Company's profile at www.sedarplus.ca. Asep Medical Holdings Inc. undertakes no obligation to update or revise any forward-looking statements, except as

required by applicable law.